

Contents

Introduction: Bioassays – Past Uses and Future Potential  
J.W. BLACK ..... 1

**Section I: Classical Pharmacology and Isolated Tissue Systems**

CHAPTER 1

**Human Vascular Receptors in Disease: Pharmacodynamic Analyses in Isolated Tissue**

J.A. ANGUS. With 25 Figures ..... 15

A. Introduction ..... 15

B. Receptors Mediating Coronary Artery Contraction: Role in Variant Angina ..... 16

    I. Large Coronary Arteries ..... 16

        1. Ergometrine ..... 16

        2. 5-HT and Endothelium-Derived Relaxing Factor ..... 16

    II. Small Resistance Arteries ..... 21

    III. Summary and Future Work ..... 27

C. Vascular Reactivity in Human Primary Hypertension and Congestive Heart Failure ..... 28

    I. The Technique, Function and Structure ..... 28

    II. Remodelling ..... 29

    III. Endothelial Dysfunction ..... 31

    IV. Forearm Veins in Primary Hypertension ..... 33

    V. Chronic Heart Failure ..... 34

D. Pharmacology of Vascular Conduits for Coronary-Bypass Graft Surgery ..... 37

    I. Introduction ..... 37

    II. Internal Mammary Artery ..... 38

    III. Saphenous Vein ..... 41

E. Human Vascular-to-Cardiac Tissue Selectivity of L- and T-Type VOCC Antagonists ..... 41

References ..... 47

## CHAPTER 2

**Problems in Assigning Mechanisms: Reconciling the Molecular and Functional Pathways in  $\alpha$ -Adrenoceptor-Mediated Vasoconstriction**

M.J. LEW. With 6 Figures .....	51
A. Introduction .....	51
B. Coupling Mechanisms at the Molecular and Cellular Levels .....	52
I. $\alpha_1$ -Adrenoceptors .....	52
II. $\alpha_2$ -Adrenoceptors .....	54
C. Coupling Mechanisms in the Intact Animal .....	56
D. Reconciliation .....	59
E. Myogenic Activation .....	61
F. Autocrine and Paracrine Activation .....	62
G. Functional Antagonism .....	64
H. Adenylate Cyclase and $\alpha_2$ -Adrenoceptors .....	66
I. Conclusions .....	68
References .....	69

## CHAPTER 3

**G<sub>s</sub> Protein-Coupled Receptors in Human Heart**

A.J. KAUMANN. With 10 Figures .....	73
A. Introduction .....	73
B. Receptor Subtypes .....	73
C. $\beta$ -Adrenoceptor Subtypes .....	74
I. Comparison of $\beta_1$ - and $\beta_2$ -Adrenoceptors .....	74
1. Localisation .....	74
2. Function of $\beta_1$ - and $\beta_2$ -Adrenoceptors .....	74
3. Selective Coupling of $\beta_2$ -Adrenoceptors .....	75
D. Is There a Functional role for Cardiac $\beta_3$ -Adrenoceptors? .....	80
I. Evidence Against Cardiostimulation .....	80
II. Evidence for Cardiostimulation .....	81
III. Evidence for Cardiodepression .....	81
IV. Evidence Against Cardiodepression .....	82
E. Cardiostimulant Effects Through the Putative $\beta_4$ -Adrenoceptor... ..	82
I. Non-Conventional Partial Agonists .....	82
II. The Putative $\beta_4$ -Adrenoceptor Resembles – But Is Distinct from – the $\beta_3$ -Adrenoceptor .....	84
III. Which Endogenous Agonist for the Putative $\beta_4$ - Adrenoceptor? .....	87
IV. The Putative $\beta_4$ -Adrenoceptor is a Special State of the $\beta_1$ -Adrenoceptor .....	88
F. 5-HT <sub>4</sub> Receptors .....	90
I. Coupling to a cAMP Pathway .....	90
II. 5-HT <sub>4</sub> -like Receptors .....	91

G. Cross-Talk Between Cardiac $G_s$ -Coupled Receptors, as Revealed by Chronic Blockade of $\beta_1$ -Adrenoceptors . . . . .	95
H. Physiological, Pathophysiological and Therapeutic Relevance . . . . .	101
I. $\beta_1$ - and $\beta_2$ -Adrenoceptors . . . . .	101
II. Putative $\beta_4$ -Adrenoceptors . . . . .	105
III. 5-HT <sub>4</sub> Receptors . . . . .	105
I. Epilogue . . . . .	107
References . . . . .	108

## Section II: New Theoretical Concepts and Molecular Mechanisms of Receptor Function

### CHAPTER 4

#### Kinetic Modeling Approaches to Understanding Ligand Efficacy

J.J. LINDERMAN. With 19 Figures . . . . .	119
A. Introduction . . . . .	119
B. Background . . . . .	120
I. Efficacy . . . . .	120
II. Modeling . . . . .	121
1. Equilibrium, Steady State, and Kinetic Models . . . . .	122
2. Diffusion-Versus Reaction-Controlled Events . . . . .	123
3. Model Structures and Dose-Response Curves . . . . .	124
C. Parameters Contributing to Ligand Efficacy . . . . .	126
I. The Lifetime of the Individual Receptor-Ligand Complex ( $1/k_r$ ) . . . . .	126
II. The Receptor Desensitization Rate Constant $k_x$ . . . . .	131
III. The Ligand Binding and Dissociation Rate Constants at Endosomal pH . . . . .	134
IV. Rate Constants in a Ternary Complex Model . . . . .	139
D. Concluding Remarks . . . . .	143
References . . . . .	144

### CHAPTER 5

#### The Evolution of Drug-Receptor Models: The Cubic Ternary-Complex Model for G Protein-Coupled Receptors

T. KENAKIN, P. MORGAN, M. LUTZ, and J. WEISS. With 7 Figures. . . . .	147
A. Receptor Models . . . . .	147
B. The Ternary Complex Model of Receptor Function . . . . .	148
C. Two-State Theory . . . . .	149
D. The Extended Ternary Complex Model . . . . .	151
E. The CTC Model . . . . .	152

F. General Application of the Cubic Model .....	155
I. Evidence for the AriG Complex .....	158
G. Conclusion .....	163
References .....	163

## CHAPTER 6

### **Inverse Agonism**

R. BOND, G. MILLIGAN, and M. BOUVIER .....	167
A. Background .....	167
B. Overexpression, Spontaneous Activity and Inverse Agonism ....	168
C. Mutations and Diseases of Spontaneous Receptor Activity .....	173
D. Modulation of Receptor Function by Agonists and Inverse Agonists .....	174
E. Models .....	177
F. Summary and Conclusions .....	178
References .....	178

## CHAPTER 7

### **Efficacy: Molecular Mechanisms and Operational Methods of Measurement. A New Algorithm for the Prediction of Side Effects**

T. KENAKIN. With 17 Figures .....	183
A. Introduction .....	183
B. The Molecular Nature of Efficacy .....	183
C. Positive and Negative Efficacy .....	186
D. The Operational Measurement of Relative Efficacy .....	188
I. Binding Studies .....	188
1. Guanosine Triphosphate $\gamma$ S Shift .....	188
2. High-Affinity Selection Binding .....	191
II. Function .....	192
1. The Method of Furchgott .....	195
2. The Method of Stephenson .....	196
3. Comparison of Relative Maximal Responses .....	197
E. Limitations of Agonist Potency Ratios .....	201
F. Why Measure the Relative Efficacies of Agonists? .....	204
G. A Simple Algorithm for the Prediction of Agonist Side Effects Using Efficacy and Affinity Estimates .....	206
I. Therapeutic Versus Secondary Agonism: Side Effect Versus Coupling Constant Profiles .....	208
II. Algorithm for Calculation of Relative $\beta_{50}$ .....	210
III. Application of the Algorithm to $\beta_3$ -Adrenoceptor Agonists .....	212
IV. Limitations of the Algorithm .....	214

H. Conclusions .....	215
References .....	215

## CHAPTER 8

### **A Look at Receptor Efficacy. From the Signalling Network of the Cell to the Intramolecular Motion of the Receptor**

H.O. ONARAN, A. SCHEER, S. COTECCHIA, and T. COSTA.

With 12 Figures .....	217
A. Introduction .....	217
B. Biological Receptors and the Dualism of Affinity and Efficacy ...	217
I. Signal Transfer and Conformational Change in Membrane Receptor .....	217
II. The Distinction Between Affinity and Efficacy .....	218
III. Generality of the Concept of Efficacy in Functional Proteins .....	219
IV. Asking the Questions .....	219
V. Two Flavours in the Definition of Efficacy: Biological and Molecular .....	220
C. Biological Definitions of Efficacy .....	221
I. The Nature of Signal Strength .....	221
II. Stimulus–Response Relationships .....	222
III. The Scale of Agonism and Antagonism .....	223
IV. Steps of Signal Transduction and the Indeterminacy of Stimulus–Response Relationships .....	225
D. Molecular Definitions of Efficacy .....	227
I. A Molecular Link Between Affinity and Efficacy .....	227
II. Allosteric Equilibrium, Free-Energy Coupling, and Thermodynamic Definitions of Efficacy .....	227
III. Linkage Between Macroscopic Perturbations in the Receptor .....	231
IV. Functional and Physical States in Proteins .....	233
V. Microscopic Interpretation of Allosteric Equilibrium .....	235
E. A Stochastic Model of Molecular Efficacy .....	238
I. Protein Motion and Fluctuations in Its Conformational Space .....	238
II. Probability Distribution of Microscopic States and Derivation of Macroscopic Constants .....	238
III. Probabilistic Interpretation of Ligand Efficacy .....	241
IV. Relationship Between Physical States and Biological Function .....	244
V. Relationship Between Efficacy and Fluorescence Changes in $\beta_2$ -Adrenoceptors .....	244
VI. Correlated Macroscopic Changes in Constitutively Active Adrenoceptors .....	248
References .....	254

## CHAPTER 9

**Mechanisms of Non-Competitive Antagonism and Co-Agonism**

D.G. TRIST and M. CORSI. With 9 Figures .....	261
A. Non-Competitive Antagonism .....	261
I. Definition .....	261
II. Analysis of the Effect of Non-Competitive Antagonists .....	261
B. Co-Agonism .....	267
I. Theory as Applied to the Glutamate NMDA Receptor .....	267
1. Evidence for Co-Agonism .....	267
2. The Theory of Co-Agonism .....	268
3. The Effect of Competitive Antagonism on Co-Agonism ...	271
4. The Effect of a Non-Competitive Antagonist on the Response of Co-Agonists .....	273
II. Experimental Data Supporting the Concept of Co-Agonism and Its Antagonism .....	274
1. Recombinant Experiments .....	274
2. Tissue Experiments .....	276
III. Implications of Co-Agonism .....	278
C. General Observations .....	279
References .....	280

## CHAPTER 10

**Mechanisms of Receptor Activation and the Relationship to Receptor Structure**

D.M. PEREZ and S.S. KARNIK. With 2 Figures .....	283
A. Introduction .....	283
B. Common GPCR Structure/Function .....	283
C. Rhodopsin and bR Activation: Light as the Ligand .....	286
I. Direct Structural Information .....	287
II. The Activation Mechanism .....	288
1. How Retinal Binds .....	288
2. Salt-Bridge Constraining Factor: Movement of TM3 and TM6 .....	289
D. AR Activation: Small Organics as Ligands .....	291
I. Important Binding Contacts of the Endogenous Ligands ....	291
II. Insights on How Epinephrine Activates .....	293
1. Release of Constraining Factors .....	293
2. Evidence for a Salt-Bridge as a Constraint: Movement of TM3 and TM7 .....	294
3. Evidence for Multiple Activation States or Mechanisms ...	296
4. Evidence for Additional Constraining Factors: Movement of TM5 and TM6 .....	296
E. Angiotensin-Receptor Activation: Peptides as Ligands .....	298

I. Peptide-Hormone GPCRs: How the Peptide Binds .....	298
II. The Ang-II Receptor .....	298
III. How AngII Peptides and Non-Peptides Bind .....	299
IV. Insights into AngII Activation .....	300
1. Role of His256 in TM6 .....	300
2. Release of Constraining Factors: Role of TM3 .....	300
F. The Ties that Bind: Concluding Remarks .....	302
I. Conservation of Critical Binding Contacts and Resulting Helical Movements .....	302
II. Conservation of Switches that Control Attainment of the Active State(s) .....	302
References .....	304

### **Section III: New Technologies for the Study of Drug Receptor Interaction**

#### **CHAPTER 11**

#### **The Assembly of Recombinant Signalling Systems and Their Use in Investigating Signaling Dynamics**

S.M. LANIER. With 4 Figures .....	313
A. Introduction .....	313
B. Assembly of Recombinant Signaling Systems .....	314
I. Stable Transfection .....	314
II. Transient Expression Systems .....	316
C. Drug–Receptor Interactions in Recombinant Signaling Systems .....	318
I. Cell-Type-Specific Signaling Events .....	318
II. Influence of Accessory Proteins .....	323
D. Perspective .....	328
References .....	328

#### **CHAPTER 12**

#### **Insect Cell Systems to Study the Communication of Mammalian Receptors and G Proteins**

R.T. WINDH, A.J. BARR, and D.R. MANNING. With 4 Figures .....	335
A. Introduction .....	335
I. Selectivity of Receptor–G Protein Interactions .....	335
II. Effector Modulation as a Measure of G Protein Activity ....	336
III. Direct Measures of G Protein Activity .....	337
B. Insect Cell Expression Systems .....	338
I. Expression of Receptors in Insect Cell Lines .....	338

II. Interaction of Receptors with Endogenous G Proteins and Effectors .....	342
III. Quantitation of Coupling Using Radioligand Binding .....	343
C. Reconstitution of Mammalian Receptors and G Proteins: Reconstituted Properties of Ligand Binding .....	345
I. Influence of Heterotrimeric G Proteins on Binding of Agonists .....	346
II. Influence of Individual G Protein Subunits on Binding of Agonists .....	348
III. Characterization of Inverse Agonism .....	349
D. Reconstitution of Mammalian Receptors and G Proteins: G Protein Activation .....	350
I. Activation Following Co-Expression of Receptor and G Protein .....	350
II. Activation Following Addition of Purified G Protein to Membranes .....	354
III. Limitations and Technical Considerations .....	355
E. Conclusions .....	356
F. References .....	356

## CHAPTER 13

### **Altering the Relative Stoichiometry of Receptors, G Proteins and Effectors: Effects on Agonist Function**

G. MILLIGAN .....	363
A. Introduction .....	363
I. Background .....	363
II. Systems to Modulate GPCR–G Protein–Effector Stoichiometries .....	364
III. Cellular Distribution of Elements of G Protein-Coupled Signaling Cascades .....	365
B. GPCR–G Protein Fusion Proteins. A Novel Means to Restrict and Define the Stoichiometry of Expression of a GPCR and a G Protein $\alpha$ Subunit .....	367
C. G Protein-Coupled Receptors .....	370
D. $G_s\alpha$ .....	376
E. Effector Enzymes: Adenylyl Cyclase .....	380
F. Conclusions .....	383
References .....	383



## CHAPTER 14

**The Study of Drug-Receptor Interaction Using Reporter Gene Systems in Mammalian Cells**

D.M. IGNAR and S. REES. With 10 Figures .....	391
A. Reporter Systems .....	391
I. What is a Reporter Gene System? .....	391
II. Detection Methods .....	391
1. Enzymatic .....	391
2. Non-Enzymatic .....	393
III. Measurement of Intracellular Signaling .....	393
1. Inducible Reporter Genes .....	393
a) Responsive Promoters .....	393
b) Chimeric Transcription Factors .....	395
2. Reporter Proteins .....	397
IV. Transient Versus Stable Expression of Reporter Genes .....	400
1. Transient Expression .....	400
2. Stable Expression .....	400
B. Use of Reporter Gene Systems in Pharmacology .....	401
I. Drug Discovery .....	401
II. Receptor Pharmacology .....	401
1. Use of Reporter Gene Assays to Assess Receptor Agonism .....	402
a) Example 1. 6CRE-Luciferase as a Reporter for $G\alpha_s$ -Coupled Receptor Signaling .....	402
b) Example 2. Aequorin as a Reporter for $G\alpha_{q/11}$ -Coupled Receptor Signaling .....	402
c) Example 3. The Use of a Gal4/Elk-1 Chimera to Report Opioid-Receptor-Like Receptor-1 Activation of MAPK .....	405
2. Use of Reporter Gene Assays to Evaluate Receptor Antagonism .....	405
3. Simultaneous Detection of Multiple Signals .....	405
a) Example 1. Dual Reporter Assays .....	405
b) Example 2. Combination of Reporter Assays with Other Assay Types .....	407
4. Measurement of Constitutive Activity .....	409
5. Measurement of Efficacy .....	411
6. Assessment of New Signaling Pathways .....	411
References .....	412

## CHAPTER 15

**Melanophore Recombinant Receptor Systems**

C.K. JAYAWICKREME and M.R. LERNER. With 7 Figures .....	415
A. Introduction .....	415
B. Cellular Signaling in Melanophores .....	417
I. Signaling Pathways .....	417
II. Endogenous Receptor Signaling .....	419
1. Melatonin 1c Receptor .....	421
2. $\alpha$ -Melanocyte Stimulating Hormone (MSH) Receptor ....	421
3. Endothelin-C Receptor .....	422
4. Serotonin Receptor .....	422
5. $\beta$ -Adrenoreceptor .....	422
6. VIP Receptor .....	423
C. Melanophore Assay Technology .....	423
I. Cell Culture and Related Techniques .....	423
1. Preparation of Cultures of Melanophore .....	423
2. Continuous Culturing of <i>Xenopus laevis</i> Melanophores ...	424
3. Receptor Expression .....	424
4. Preparation of Stable Melanophore Lines Expressing Exogenous Receptors .....	425
II. Signal Detection .....	425
1. Transmittance Reading .....	425
2. Digital Imaging .....	426
III. Screening Formats .....	427
1. Microtiter Well Format .....	427
2. Lawn Format .....	428
IV. Receptor Cloning and Mutagenesis Studies .....	428
D. Receptor Studies and Applications .....	429
I. Characterization of Novel GPCRs .....	431
II. Lawn Format Screen System .....	432
III. Single Transmembrane Receptors .....	433
IV. Receptor-Ligand Interaction Studies .....	434
E. Summary .....	435
References .....	435
Subject Index .....	441

The Pharmacology of Functional, Biochemical, and  
Recombinant Receptor Systems

Kenakin, T.; Angus, J.A. (Eds.)

2000, XX, 448 p., Hardcover

ISBN: 978-3-540-66124-5